| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/13/2000 | WO2000040559A1 Compositions for the treatment of skin diseases |
| 07/13/2000 | WO2000040557A1 Process for the formation of intermediates useful for the preparation of pharmaceuticals |
| 07/13/2000 | WO2000040554A1 Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression |
| 07/13/2000 | WO2000040552A1 Amidomalonamides and their use as inhibitors of matrix metalloproteinase |
| 07/13/2000 | WO2000040548A1 Arylalkanoyl derivatives, processes for their preparation, their use and pharmaceutical compositions containing them |
| 07/13/2000 | WO2000040546A1 Process for producing acidic n-(long-chain acyl)amino acid |
| 07/13/2000 | WO2000040543A1 Skin whitener |
| 07/13/2000 | WO2000040539A1 Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors for the treatment of respiratory diseases |
| 07/13/2000 | WO2000040529A1 Colchinol derivatives as vascular damaging agents |
| 07/13/2000 | WO2000040272A2 P450 / acetaminophen gdept for cancer treatment |
| 07/13/2000 | WO2000040271A2 P450 / acetaminophen gdept for cancer treatment |
| 07/13/2000 | WO2000040269A2 Pharmaceutical compositions for treatment of diseased tissues |
| 07/13/2000 | WO2000040268A1 Antitumor agents |
| 07/13/2000 | WO2000040267A1 Pyrimidine antimetabolite parenteral solution |
| 07/13/2000 | WO2000040265A1 Potentiation of anti-cd38-immunotoxin cytotoxicity |
| 07/13/2000 | WO2000040257A1 Method for producing an antitumoral agent and antitumoral agent thus obtained |
| 07/13/2000 | WO2000040254A1 Pharmaceutical composition for oral administration having therapeutic activity on gastrointestinal disorders |
| 07/13/2000 | WO2000040252A1 Novel polymer formulations containing perfluorinated compounds for the engineering of cells and tissues for transplantation that improves cell metabolism and survival, and methods for making same |
| 07/13/2000 | WO2000040251A1 Use of adenosine agonists in cancer therapy |
| 07/13/2000 | WO2000040249A1 Use of estrone as an anti-emetic agent |
| 07/13/2000 | WO2000040248A1 Method and composition for treatment of female sexual dysfunction |
| 07/13/2000 | WO2000040247A1 2-oxy-benzoxazinone derivatives for the treatment of obesity |
| 07/13/2000 | WO2000040245A1 Method of using (2-imidazolin-2-ylamino) quinoxalines in treating neural injury |
| 07/13/2000 | WO2000040244A1 Use of phanquinone for the treatment or prevention of memory impairment |
| 07/13/2000 | WO2000040243A1 Novel compounds |
| 07/13/2000 | WO2000040242A2 Preparation of a composition against hepatitis b-, hi-, paramyxo- and orthomyxoviruses |
| 07/13/2000 | WO2000040241A2 Treatment and prevention of reactive oxygen metabolite-mediated cellular damage |
| 07/13/2000 | WO2000040240A1 Methods and compositions for topical treatment of damaged tissue using reactive oxygen metabolite production or release inhibitors |
| 07/13/2000 | WO2000040239A1 Compounds and methods |
| 07/13/2000 | WO2000040238A1 Pharmaceutical formulations of taxanes |
| 07/13/2000 | WO2000040237A1 Antiviral method using mek inhibitors |
| 07/13/2000 | WO2000040236A1 Stabile and sterile emulsion which contains taxanes, and method for the production thereof |
| 07/13/2000 | WO2000040235A2 Treatment of asthma with mek inhibitors |
| 07/13/2000 | WO2000040234A1 Topical anesthesia of the urinary bladder |
| 07/13/2000 | WO2000040233A1 Pharmaceutical composition containing metformin, acarbose or glimepiride and optionally poly-(dimethyl)-siloxane |
| 07/13/2000 | WO2000040232A2 Bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions |
| 07/13/2000 | WO2000040231A1 Composition and method for enhancing male fertility and libido |
| 07/13/2000 | WO2000040230A2 Hormone replacement for breast cancer patients |
| 07/13/2000 | WO2000040229A2 Synergistic tumorcidal response induced by histamine |
| 07/13/2000 | WO2000040228A2 Formulations comprising imiquimod or other immune response modifiers for treating mucosal conditions |
| 07/13/2000 | WO2000040227A2 Methods for treating conditions associated with the accumulation of excess extracellular matrix |
| 07/13/2000 | WO2000040226A2 Method of treating sexual disturbances |
| 07/13/2000 | WO2000040225A2 Inhibition of tnf activity |
| 07/13/2000 | WO2000040224A1 Multiparticulate oral dosage forms |
| 07/13/2000 | WO2000040220A1 Method of preparing pharmaceutical active ingredient comprising water-insoluble drug and pharmaceutical composition for oral administration comprising the same |
| 07/13/2000 | WO2000040217A1 Topical composition comprising n-acetylaldosamines or n-acetylamino acids |
| 07/13/2000 | WO2000040215A1 Cosmetic or dermatological composition containing an active principle stimulating hsp 32 protein synthesis in the skin and cosmetic treatment method |
| 07/13/2000 | WO2000040210A2 Topical compositions comprising protected functional thiols |
| 07/13/2000 | WO2000040205A2 Sustained release formulation with reduced moisture sensitivity |
| 07/13/2000 | WO2000040172A1 Composition and formulations and their use as nociceptic, anti-anxiolytic and anabolic agents |
| 07/13/2000 | WO2000040089A1 Targeted transscleral controlled release drug delivery to the retina and choroid |
| 07/13/2000 | WO2000040088A1 Amide derivatives for antiangiogenic and/or antitumorigenic use |
| 07/13/2000 | WO2000040087A1 Converting cox inhibition compounds that are not cox-2 selective inhibitors to derivatives that are cox-2 selective inhibitors |
| 07/13/2000 | WO2000040086A1 Formulations for treating disease and methods of using same |
| 07/13/2000 | WO2000027405A8 Hyaluronic acid gel, process for the preparation thereof and medical materials containing the same |
| 07/13/2000 | WO2000027363B1 Aerosols comprising nanoparticle drugs |
| 07/13/2000 | WO2000025764A3 Compositions for the treatment and prevention of cardiovascular diseases |
| 07/13/2000 | WO2000024741A3 Dihydropyridine compounds and their use as potassium channel openers |
| 07/13/2000 | WO2000023063A3 Methods for inhibiting diabetic complications |
| 07/13/2000 | WO2000022121A3 Ion channels, in particular vanilloid receptor-like (vr-l) receptor |
| 07/13/2000 | WO2000021986A3 Matrix-remodeling genes |
| 07/13/2000 | WO2000021927A3 Pyrrole-2,5-diones as gsk-3 inhibitors |
| 07/13/2000 | WO2000021487A3 Formoterol polymorphs |
| 07/13/2000 | WO2000018351A3 Aglyco products and methods of use |
| 07/13/2000 | WO2000017366A3 Pharmaceutical composition for the pre-treatment of a patient in need of drug or pro-drug |
| 07/13/2000 | WO2000015208A3 New use of immunosupressants for mmp-mediated diseases |
| 07/13/2000 | WO2000015204A3 Use of benzenesulfonyl(thio)ureas for the treatment and prophylaxis of dysfunctions of the autonomous nervous system and use of benzenesulfonyl(thio)ureas in combination with beta-receptor blockers |
| 07/13/2000 | WO2000015174A3 Bioflavonoid as blood glucose level lowering agent |
| 07/13/2000 | WO2000014217A3 G-motif oligonucleotides and uses thereof |
| 07/13/2000 | WO2000013683A3 Novel nitrophenylaziridine compounds and their use as prodrugs |
| 07/13/2000 | WO2000013648A3 Method for the preparation of citalopram |
| 07/13/2000 | WO2000012517A9 Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof |
| 07/13/2000 | WO2000010958A9 Vitamin d3 mimics |
| 07/13/2000 | WO2000010582A3 Probiotic, lactic acid-producing bacteria and uses thereof |
| 07/13/2000 | WO2000009734A9 Methods and compositions for use in spliceosome mediated rna trans-splicing |
| 07/13/2000 | WO2000008020A3 Tricyclic carboxamides |
| 07/13/2000 | WO2000006534A9 Compounds and compositions for delivering active agents |
| 07/13/2000 | WO2000003737A9 Water-soluble drugs and methods for their production |
| 07/13/2000 | WO1999058096A9 Analogs of 2-phthalimidinoglutaric acid and their use as inhibitors of angiogenesis |
| 07/13/2000 | WO1999055162A8 Method for the treatment of viral disease |
| 07/13/2000 | WO1997020575A8 Targeted adenovirus vectors |
| 07/13/2000 | DE19900749A1 A topically applied film-forming composition contains antiandrogenic N-phenyl-azolidine compound, used for treating hirsutism, seborrhea, acne or especially androgenetic alopecia |
| 07/13/2000 | DE19900743A1 Neue komplexbildende Proteine New complexing proteins |
| 07/13/2000 | DE19900674A1 Bindungspartner für 5-HT5-Rezeptoren zur Migränebehandlung Binding partners for 5-HT5 receptors in migraine treatment |
| 07/13/2000 | DE19900673A1 Verwendung von Bindungspartnern für 5-HT5-Rezeptoren zur Behandlung neurodegenerativer und neuropsychiatrischer Störungen Use of binding partners for 5-HT5 receptors for the treatment of neurodegenerative and neuropsychiatric disorders |
| 07/13/2000 | DE19900545A1 Verwendung von Pyrimidinderivaten zur Prophylaxe und Therapie der zerebralen Ischämie Use of pyrimidine derivatives for the prophylaxis and therapy of cerebral ischemia |
| 07/13/2000 | DE19900544A1 Verwendung von Verbindungen der Formel I zur Prophylaxe und Therapie der zerebralen Ischämie Use of compounds of formula I for the prophylaxis and therapy of cerebral ischemia |
| 07/13/2000 | DE19900471A1 Imidazo[4,5c]-pyridin-4-on-derivate Imidazo [4,5c] pyridin-4-one derivatives |
| 07/13/2000 | DE19845405C2 Arylsubstituierte Propanolaminderivate und deren Verwendung Aryl-substituted Propanolaminderivate and their use |
| 07/13/2000 | CA2778317A1 Topical composition comprising n-acetylaldosamines or n-acetylamino acids |
| 07/13/2000 | CA2360396A1 Characterization of a calcium channel family |
| 07/13/2000 | CA2359989A1 1-phenyl-4-(1-¬2-aryl|cyclopropyl) methylpiperazines: dopamine receptor ligands |
| 07/13/2000 | CA2358962A1 Process for preparing n6-substituted deaza-adenosine derivatives |
| 07/13/2000 | CA2358955A1 N-carboxymethyl substituted benzolactams as inhibitors of matrix metalloproteinase |
| 07/13/2000 | CA2358939A1 3-(thio-substituted amido)-lactams useful as inhibitors of matrix metalloproteinase |
| 07/13/2000 | CA2358851A1 Treatment and prevention of reactive oxygen metabolite-mediated cellular damage |
| 07/13/2000 | CA2358754A1 Synergistic tumorcidal response induced by histamine |
| 07/13/2000 | CA2358594A1 Novel derivatives from the class of oleandomycin |
| 07/13/2000 | CA2358586A1 Tetrahydroindazole derivatives as ligands for gaba-a alpha 5 receptors |
| 07/13/2000 | CA2358578A1 Novel malonic acid derivatives, processes for their preparation, their use and pharmaceutical compositions containing them (inhibition of factor xa activity) |